Genmab, Seattle expand ADC collaboration with HuMax-CD74
This article was originally published in Scrip
Danish antibody specialist Genmab has reaffirmed the more active partnering strategy instituted last year by new chief executive officer Dr Jan van de Winkel, expanding its research collaboration with Seattle Genetics for antibody-drug conjugates (ADCs) to add a new anticancer candidate to its preclinical pipeline.
You may also be interested in...
In a six-year-old collaboration with Genmab, Seattle Genetics has decided to exercise its option to co-develop and co-commercialize tisotumab vedotin, an antibody-drug conjugate for solid tumors, granting both companies a 50:50 share.
Policies, programs and strategies promoting diversity and inclusion are almost as ubiquitous in the pharmaceutical industry these days as environmental commitments. That reflects enormous cultural change over the last few generations, hastened in recent history by initiatives such as MeToo or Black Lives Matter.
HemaQuest, a US biotech focused on developing small-molecule therapeutics for haemoglobin diseases, has expanded the Phase II programme for its lead compound, HQK-1001, in sickle cell disease with a new trial aimed at establishing safety and tolerability at higher dose levels and over a longer course of therapy.